drugset / Trial / NCT01465919

Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C

NCT01465919

Phase 4 Terminated 5 enrolled Seoul National University Boramae Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the anti-depressive efficacy of mirtazapine in depression induced by peginterferon alpha-2a and ribavirin treatment in Korean patients with chronic hepatitis C.

Timeline

Start
2011-08
Primary completion
2017-12
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirtazapine Other / unclassified 7.5 mg
Subject Mirtazapine Other / unclassified 45 mg

Indications